Navigation Links
Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proacta's PR509 Compound
Date:2/22/2011

SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd. (Tokyo: 2267) today announced the execution of a definitive agreement relating to the collaborative research, development and commercialization of Proacta's PR509, a hypoxia-activated pro-drug for the treatment of cancer.

(Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-a)

(Logo: http://photos.prnewswire.com/prnh/20110222/LA50556LOGO-b)

"We have worked diligently to arrive at this significant agreement with Yakult and we are very pleased to announce its execution," said John C. Gutheil, MD, Proacta's CEO. "This achievement underscores the commitment that our two companies have to a long-term, mutually rewarding relationship. It also exemplifies the ability of Proacta to leverage relationships with pharmaceutical partners to foster the likelihood of market success for its proprietary line of hypoxia-activated pro-drugs. We view this partnership with Yakult as further validation of the hypoxia-activated pro-drug platform and its potential as a novel therapeutic agent for patients suffering from cancer."

Mr. Shigeyoshi Sakamoto, Head, Pharmaceutical Division/ Managing Director, Member of the Board of Yakult, said, "We are delighted to have reached an agreement with Proacta regarding their PR509 for the research, development, and commercialization in Japan. The unique mechanism of action and well-developed preclinical data provide Yakult with the confidence necessary to join with Proacta in completing the preclinical and early clinical studies in the US in a collaborative manner. This collaboration should allow us to more quickly bring promising new treatments to patients suffering from cancer. We look forward to our work with Proacta through the collaborative research and development of PR509."

About PR509

PR509 is Proacta's proprietary hypoxia-activated irreversible multi-kinase inhibitor discovered at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand.  Reversible multi-kinase inhibitors (MKI) are currently in use for the treatment of several types of cancer.  However, resistance often develops to reversible MKI's.  In addition, reversible MKI's have side effects that limit the use of higher doses.  PR509 utilizes an irreversible MKI that is activated only in areas of severe hypoxia, a characteristic of most solid tumors.  Localized release of the irreversible MKI leads to higher concentrations in the tumor relative to normal tissues, which should result in improved efficacy and fewer side effects.  In addition, irreversible MKI inhibitors are not subject to some of the resistance mechanisms applicable to reversible MKI inhibitors.

Clinical Development Status

PR509 is currently targeted for development in non-small cell lung cancer resistant to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib, where an effective treatment has yet to be established.  In addition to NSCLC, Proacta expects to evaluate PR509 in other cancers such as gastric, breast, and pancreatic that are currently treated with first-generation reversible tyrosine kinase inhibitors.

About Proacta Incorporated

Proacta is a San Diego based biotechnology company dedicated to the development and commercialization of hypoxia-activated oncology drugs. Proacta is currently conducting a phase II study of PR104, a hypoxia activated alkylator, in patients with relapsed or refractory leukemia.  In addition, Proacta has a pipeline of hypoxia-activated prodrugs for the treatment of cancer that are licensed from the University of Auckland in New Zealand.  For more information on Proacta, visit the Proacta web site at www.proacta.com.

About Yakult

Yakult is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics. With respect to its pharmaceutical business, Yakult has an emerging presence in oncology. For more information on Yakult, visit: http://www.yakult.co.jp/english/index.html or view the following company profile:

http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf


'/>"/>
SOURCE Proacta Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DJO Incorporated Completes Business Integration and Changes Name to DJO Global, Inc.
2. DJO Incorporated Announces Planned Transition of President and CEO Les Cross
3. DJO Incorporated Acquires Manufacturer of Compression Therapy Products, Elastic Therapy, Inc.
4. Accuray Incorporateds CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference
5. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
6. Accuray Incorporated to Speak at Oppenheimers 21st Annual Healthcare Conference
7. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2011
8. Accuray Incorporated to Host Analyst Meeting at ASTRO 2010
9. Accuray Incorporated to Speak at JMP Securities Healthcare Conference
10. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
11. Havels Incorporated Helping to Reduce Radiation Exposure with New EchoTuohy™ Ultrasound Needle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):